UNITED ~~STATES~~STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

~~SECURITIES~~Form ~~AND EXCHANGE COMMISSION~~6-K

~~Washington,~~REPORT ~~D.C.~~OF ~~20549~~FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

~~FORM~~For ~~6-K~~the month of May 2024

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2024

Commission File Number: 001-39458

Medicenna Therapeutics Corp.(Translation of registrant's name into English)

2 Bloor St. W., 7th FloorToronto, Ontario M4W 3E2, Canada(~~Translation~~Address of ~~registrant’s~~principal ~~name~~executive ~~into English~~office)

2Indicate ~~Bloor~~by ~~St.~~check Wmark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.Form ~~7th~~20-F ~~Floor~~[ X ] Form 40-F [ ]

~~Toronto,~~EXHIBIT ~~Ontario M4W 3E2~~INDEX

Canada

Exhibit Number		Description

99.1		Press Release dated May 13, 2024

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

x Form 20-F ¨ Form 40-F

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Medicenna Therapeutics Corp.
	(Registrant)
Date: May 13, 2024	By:	/s/ Fahar Merchant, PhD
Date: April 30, 2024	By:	/s/ Fahar Merchant
		Name: Fahar Merchant, PhD
		Name:	Fahar Merchant, PhD
		Title: Chief Executive Officer
		Title:	Chief Executive Officer

Form 6-K Exhibit Index

Exhibit Number		Document Description
99.1		Press Release of the Registrant dated April 30, 2024
99.2		Material Change Report of the Registrant dated April 30, 2024
99.3		Pre-Funded Warrant Certificate

Filing Compare · Medicenna Therapeutics Corp.